MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

Evangelos Triantafyllou,1,2,3 Oltin T Pop,1 Lucia A Possamai,2 Annika Wilhelm,2 Evaggelia Liaskou,3 Arjuna Singanayagam,1,2 Christine Bernsmeyer,1 Wafa Khamri,2 Gemma Petts,2 Rebecca Dargue,4 Scott P Davies,3 Joseph Tickle,3 Muhammed Yuksel,1 Vishal C Patel,1 Robin D Abeles,1 Zania Stamataki,3 Stuart M Curbishley,3 Yun Ma,1 Ian D Wilson,4 Muireann Coen,4 Kevin J Woollard,5 Alberto Quaglia,1 Julia Wendon,1 Mark R Thursz,2 David H Adams,3 Chris J Weston,3 Charalambos G Antoniades1,2,3

ABSTRACT
Objective Acute liver failure (ALF) is characterised by overwhelming hepatocyte death and liver inflammation with massive infiltration of myeloid cells in necrotic areas. The mechanisms underlying resolution of acute hepatic inflammation are largely unknown. Here, we aimed to investigate the impact of Mer tyrosine kinase (MerTK) during ALF and also examine how the microenvironmental mediator, secretory leucocyte protease inhibitor (SLPI), governs this response.

Design Flow cytometry, immunohistochemistry, confocal imaging and gene expression analyses determined the phenotype, functional/transcriptomic profile and tissue topography of MerTK+ monocytes/macrophages in ALF, healthy and disease controls. The temporal evolution of macrophage MerTK expression and its impact on resolution was examined in APAP-induced acute liver injury using wild-type (WT) and Mer-deficient (Mer−/−) mice. SLPI effects on hepatic myeloid cells were determined in vitro and in vivo using APAP-treated WT mice.

Results We demonstrate a significant expansion of resolution-like MerTK+HLA-DRhigh cells in circulatory and tissue compartments of patients with ALF. Compared with WT mice which show an increase of MerTK+MHCIIhigh macrophages during the resolution phase in ALF, APAP-treated Mer−/− mice exhibit persistent liver injury and inflammation, characterised by a decreased proportion of resident Kupffer cells and increased number of neutrophils. Both in vitro and in APAP-treated mice, SLPI reprogrammes myeloid cells towards resolution responses through induction of a MerTK+HLA-DRhigh phenotype which promotes neutrophil apoptosis and their subsequent clearance.

Conclusions We identify a hepatoprotective, MerTK+, macrophage phenotype that evolves during the resolution phase following ALF and represents a novel immunotherapeutic target to promote resolution responses following acute liver injury.

INTRODUCTION
Acute liver failure (ALF) is a clinical syndrome caused by overwhelming hepatocyte death, often

What is already known on this subject?
► Liver inflammation is central to the pathogenesis of acute liver failure (ALF) where infiltration of myeloid cells in areas of hepatic necrosis is contrasted by systemic immune cell depletion and dysregulation.
► Mer tyrosine kinase (MerTK) regulates innate immune responses and promotes the clearance of apoptotic cells following acute tissue injury.
► Secretory leucocyte protease inhibitor (SLPI) is produced within the inflamed liver in ALF and is a key modulator of monocyte anti-inflammatory responses.

What are the new findings?
► Patients with ALF have an expansion of resolution-like MerTK+HLA-DRhigh monocytes and hepatic macrophages, characterised by suppressed innate and enhanced effectoric/phagocytic responses.
► MerTK+ monocytes exhibit a distinct pattern of adhesion, phagocytosis, pattern-recognition, and cytokine receptors and genes associated with antigen presentation and macrophage polarisation.
► A similar phenotype (MerTK+MHCIIhigh) with enhanced phagocytic capabilities evolves during the resolution phase of APAP-induced acute liver injury in mice.
► MerTK-deficient mice exhibit persistent liver injury and inflammation after APAP overdose and are characterised by a depletion in MHCIIhigh-bearing resident Kupffer cells and by increased numbers of activated neutrophils.
► SLPI reprogrammes myeloid cells towards resolution responses by inducing the prorrestorative MerTK+HLA-DRhigh phenotype which promotes neutrophil apoptosis and their subsequent clearance.

Significance of this study
leading to jaundice, encephalopathy and multiorgan dysfunction. Drug-induced liver injury, particularly acetaminophen (APAP)-induced ALF (AALF), is the most common cause of ALF, and despite liver transplantation as an option it has a high mortality rate. Although the inciting event in ALF is hepatocellular death, mortality is a consequence of activation of systemic inflammatory responses (SIRS) and its attendant complications of multi-organ failure and recurrent infection, generated by uncontrolled immune-mediated liver injury.2 3

Central to the pathogenesis of ALF is liver inflammation where the infiltration of myeloid cells in areas of centrilobular necrosis is contrasted by immune cell depletion and dysregulation.4 Due to their inherent plasticity, monocytes/macrophages execute diverse functions during tissue inflammation, at both initiation and resolution phases, and exist in numerous activation states influenced by different microenvironmental cues.5 At steady state, monocytes traffic to the liver, augmenting the local macrophage pool, a process that is markedly increased during ALF.6 7 Patients with ALF exhibit an expansion of hepatic macrophages, localised in areas of necrosis, through chemokine-dependent recruitment of monocyte-derived macrophages (MoMF) and proliferation of resident Kupffer cells (KCs).4 6–10 Studies in humans and mice indicate that hepatic macrophages orchestrate both tissue-destructive and resolution/repair responses following acute liver injury.4 6 10 11 Both resident KCs and MoMF populations are important effectors of resolution/tissue-repair processes following acute liver injury, where, in the absence of both or either of these phagocytes, there is significantly impaired recovery and clearance of intrahepatic neutrophils.6 7 12 13 14

Mer tyrosine kinase (MerTK) is a member of the Tyro3-Axl-MerTK (TAM) family of receptor tyrosine kinases expressed predominantly on macrophages.15 Following acute tissue injury, MerTK dampens innate immune responses and promotes clearance (efferocytosis) of apoptotic cells.15 Engagement and activation of MerTK inhibit signalling pathways triggered by cytokines and toll-like receptor ligands through suppression of cytokine signalling protein (SOCS)-1 and SOCS-3 signalling.16 MerTK recognises the exposed phosphatidylserine on the surface of apoptotic cells, in association with its ligands (Gas-6 and Galectin-3), while their efferocytosis induces a monocyte/macrophage functional switch towards resolution–tissue repair responses.17

Secretory leucocyte protease inhibitor (SLPI) is a small protein (11.7 kDa) secreted by epithelial and myeloid cells that can suppress monocyte/macrophage proinflammatory responses through inhibition of NF-κB signalling.18–21 SLPI is shown to exert immune-modulatory activities during tissue inflammation in a variety of inflammatory diseases such as sepsis, asthma and cancer.22 We recently identified SLPI, secreted in the liver by biliary epithelial cells and hepatic macrophages, as a modulator of circulating monocyte function in human ALF.11 In this study, we used a combination of human and murine experimental models in order to investigate the role of MerTK during resolution following acute liver injury and examine how SLPI, as a proresolving mediator, governs this immunological response in ALF.

**METHODS**

**Patients**

Patients with acetaminophen-induced ALF (AALF, n=23) and non-acetaminophen induced ALF (NAALF, n=9) were recruited to the study within 24 hours following admission to the Liver Intensive Care Unit of King’s College Hospital (London, UK). Inpatients with chronic liver disease (CLD, n=10) and healthy volunteers (HC, n=15) served as pathological and healthy controls. Exclusion criteria: age <18 or >65 years, neoplasia and immunosuppressive therapy; patients were identified for emergency transplantation according to King’s College Hospital (KCH) criteria.23 The study was approved by the National Research Ethics Service (NRES) Health Research Authority (12/LO/0167). All diseased (06/Q2708/11) and normal (06/Q2702/61) liver tissue and blood samples (04/Q2708/41) were obtained through the Liver Unit of Queen Elizabeth Hospital (Birmingham, UK) after local ethics committee approval and patient consent. Clinical, haematological and biochemical parameters were determined on a haematological analyser (Siemens Advia 2120, Berks, UK).

**Mice**

All animal experiments were conducted with approval by the Home Office and local ethics committees (PPL 70/7578, B6.129-MerTKtm1Gr1/J (Mer−/−)) and wild-type (WT) mice with an identical background (B6.129SF2/J) were obtained from The Jackson Laboratory, WT and Mer−/− mice were age-matched and sex-matched (male, 8–10-week-old) for the experiments. Mice fasted overnight received an intraperitoneal injection of APAP (300 mg/kg, Sigma-Aldrich, UK) or saline and were studied at several time points. SLPI administration in APAP mice. WT mice (male, 8–10-week-old, C57BL/6J) fasted overnight and received an intraperitoneal injection of APAP or recombinant human (rh)-SLPI (16.5 μg/kg) (R&D Systems, UK) both based on the SLPI plasma levels (8 hours post APAP) (see online supplementary methods 1). Mice sacrificed at 24 or 48 hours received a second SLPI intraperitoneal injection at 8 hours, while mice sacrificed at 48 hours received a third SLPI intraperitoneal injection at 24 hours.

**Flow cytometry**

Human monocytic and liver-derived macrophages were phenotypically characterised using flow cytometry on a fluorescence-activated cell sorting (FACS) Canto II analyser (BD Biosciences, UK), and data were analysed with FlowJo 10.1 software (Treestar, Ashland, OR). Murine liver-derived macrophages were phenotypically characterised using flow cytometry on an LSR Fortessa analyser (BD Biosciences, UK), and data were analysed with Flowlogic 600.0A software (Inivai Technologies) (see online supplementary methods 2–4).

**Gene expression analysis**

Gene expression analysis was performed using the NanoString nCounter GX Human Immunology V2 assay (NanoString Technologies, Seattle, Washington, USA) profiling 954 immunology-related genes on FACS-separated cells (see online supplementary methods 5). The differential gene expression among subsets was calculated and plotted as heat map using the nSolver Analysis Software V3.0 (NanoString Technologies, Seattle, Washington, USA). Statistically relevant results are considered with p<0.05 and a fold-change of 50% higher or lower.

**Significance of this study**

**How might it impact on clinical practice in the foreseeable future?**

- SLPI is a pivotal proresolving mediator in ALF that promotes MerTK-dependent hepatic resolution responses following acute liver injury.
- Harnessing the proresolving capabilities of MerTK+ cells represents a novel therapeutic strategy to promote resolution following acute hepatic inflammatory disorders.
Ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS) of acetaminophen and metabolites in mouse plasma

Mouse plasma samples were analysed for acetaminophen (APAP) and five metabolites (APAP-glucuronide, APAP-sulfate, APAP-cysteinyI, APAP-glutathione and APAP-N-acetylcySteineI) as detailed (see online supplementary methods 6). Samples, deproteinised via solvent precipitation, were analysed by reversed-phase gradient chromatography on an Acquity Ultra Performance Liquid Chromatography system (Waters Corporation, Manchester, UK) with selective detection via MS/MS, in positive electrospray ionisation mode, via a Waters Xevo TQ-S mass spectrometer. Quantification of each compound was relative to an appropriate deuterated internal standard (see online supplementary methods 6).

Tissue sampling and imaging

Human liver tissue was obtained from patients with ALF (n=14) undergoing orthotopic liver transplantation, a diseased liver tissue from patients with CLD (n=10), while normal liver (NL, n=6) tissue was derived from hepatic resection margins of colorectal malignancies. For phenotyping of macrophages, mononuclear cells were freshly isolated from ALF (n=8), CLD (n=10) and NL (n=6) liver tissue. For immunohistochemistry (IHC), liver and mesenteric lymph node tissues were obtained from ALF (n=6) and hepatic resections, serving as pathological controls (n=4). Single/double epitope enzymatic IHC on formalin-fixed paraffin-embedded (FFPE) tissue was performed to assess the number of positive cells for MerTK, HLA-DR, CD163, MPO and TUNEL. Double epitope fluorescent IHC was used to demonstrate colocalisation by Nuance multispectral quantification of fluorescent IHC (see online supplementary methods 7).

Cell culture and functional assays

SLPI effects on (a) monocyte migration and efferocytosis and (b) neutrophil oxidative burst and extracellular trap (NET) formation were assessed by a modified Boyden chamber assay and flow cytometry, respectively. Supernatants were preincubated with anti-SLPI antibody to determine effects on (a) monocyte migration and efferocytosis and (b) neutrophil oxidative burst and extracellular trap (NET) formation. The proportion of positive cells for MerTK, HLA-DR, CD163, MPO and TUNEL was determined by immunohistochemistry and confocal microscopy (see online supplementary methods 8).

Statistical analysis

Data analysis and graphing were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla California). Statistical significance was assessed with non-parametric analyses, and results are presented as median with IQR, unless otherwise specified in figure legends.

RESULTS

Resolution-like MerTK+ monocytes and hepatic macrophages are expanded in ALF

Using flow cytometry, we assessed the phenotype of both circulating monocytes and hepatic macrophages, freshly isolated from human explant tissue, in ALF, CLD and HC. Patients with ALF exhibit a marked increase in the proportion of MerTK+ cells, when compared with HC and CLD (table 1 and figure 1A, B). Patients with acetaminophen-induced ALF (AALF) show a higher percentage of MerTK+ monocytes, physiological and biochemical indices of disease severity, compared with those with non-acetaminophen-induced ALF (NAALF) (table 2). MerTK+ cells correlated positively with SIRS score (r=0.47; p<0.01), AST (r=0.45; p<0.01), international normalised ratio (r=0.37; p<0.01), heart rate (r=0.36; p<0.05), and negatively with bilirubin (r=−0.4; p<0.05), mean arterial pressure (r=−0.49; p<0.01) and monocyte count (r=−0.47; p<0.01).

In line with previous data,24 MerTK+ cells in ALF are characterised by a resolution-like HLA-DRhiCD163hiTie2hi immunophenotype compared with CLD and HC (figure 1C). Peak levels of MerTK+HLA-DRhi cells are detected on admission to the Liver Intensive Care Unit (figure 1D), which subsequently decline to levels similar to HC by day 3–5. In contrast to HC and CLD groups, MerTK+HLA-DRlow cells are detected and significantly elevated in circulatory and tissue compartments in patients with ALF and remain persistently elevated following their admission (figure 1D and see online supplementary figure S2A,B). Analyses of MerTK+ cells based upon their HLA-DR immunophenotype identify key differences in their functional profile. Compared with HC and MerTK+HLA-DRlow cells, MerTK+HLA-DRhi cells have an enhanced clearance of apoptotic (CMFDA+ AnnexinVhi neutrophils) and infective (pHrodo E. coli BioParticles) material, with attenuated secretion of

| Parameter                  | ALF          | CLD          | HC           |
|----------------------------|--------------|--------------|--------------|
| Number of patients         | 32           | 10           | 15           |
| Age                        | 35*          | 52           | 29*          |
| Sex (M:F)                  | [28–45]      | [44–65]      | [26–45]      |
| Aetiology                  | Drug-induced | ALD [4]      | n/a          |
|                           | Acetaminophen [23] | NAFLD [3]   |               |
|                           | Mixed overdose [2] | HFE [1]     |               |
|                           | Non-drug induced [1] | PBC [1]     |               |
|                           | Pregnancy-related [3] | PSC [1]     |               |
|                           | Budd-Chiari [1] | Hepatitis B [1] |               |
|                           | Acute Wilsons [1] | Ischaemia [1] |               |
| WCC (×109/L)               | 10.4*        | 4.46         | n/a          |
| (≥10.0–15.5)               | [6.7–15.5]   | [3.7–5.1]    |               |
| Monocytes (×109/L)         | 0.22         | 0.31         | n/a          |
|                           | [0.13–0.4]   | [0.24–0.42]  |               |
| Creatinine (μmol/L)        | 139.5**      | 73           | n/a          |
|                           | [90–242]     | [56–79]      |               |
| INR                        | 5.4***       | 1.4          | n/a          |
|                           | [2.8–8.8]    | [1.15–1.6]   |               |
| Bilirubin (μmol/L)         | 88***        | 49           | n/a          |
|                           | [49.5–177]   | [12–70]      |               |
| AST (IU/mL)                | 5199***      | 45           | n/a          |
|                           | [1155–8499]  | [28–55]      |               |
| Encephalopathy             | 2***         | 1            | n/a          |
|                           | [1–3]        | [0–1]        |               |
| Child’s Pugh               | n/a          | 9            | [8–11]       |
|                           | n/a          | [8–11]       |               |
| MELD                       | 39.5*        | 12           | [7–19]       |
|                           | [33–40]      | [7–19]       |               |
| SOFA                       | 13           | n/a          | [10–16]      |

* p=0.006; ** p=0.001; *** p<0.0001, compared with CLD group.

| Aetiology                  | PLD [1]      | HFE [1]      |
|----------------------------|--------------|--------------|
| | ALD [4] | NAFLD [3] |
| | Mixed overdose [2] | HFE [1] |
| | Non-drug induced [1] | PBC [1] |
| | Pregnancy-related [3] | PSC [1] |
| | Budd-Chiari [1] | Hepatitis B [1] |
| | Acute Wilsons [1] |Ischaemia [1] |

Hepatology

Triantafyllou E, et al. Gut 2018;67:333–347. doi:10.1136/gutjnl-2016-313615
Figure 1  Characterisation of Mer tyrosine kinase (MerTK)+ circulating monocytes and liver-derived hepatic macrophages in patients with acute liver failure (ALF). (A) Flow cytometry analysis and gating strategy used to determine MerTK expression in circulating monocytes and their subsets. (B) Data show MerTK expression levels of (1) monocytes in patients with ALF (n=15), chronic liver disease (CLD) (n=10) and healthy controls (HC) (n=15), (2) liver-derived macrophages isolated from ALF (n=8), CLD (n=10) and normal liver (n=6) tissue. (C) Representative histograms and expression levels of monocyte surface markers in MerTK+HLA-DR± cells. (D) MerTK+HLA-DR+ and MerTK+HLA-DR- subsets as proportion (%) of circulating monocytes in HC (n=15), patients with CLD (n=10) and ALF on admission (n=15) and days 3–5 following their admission (n=8). (E) Inflammatory cytokine secretion in HC and ALF peripheral blood mononuclear cells (PBMC) supernatants (n=5 each) after microbial challenge (LPS 100 ng/mL, 6 hours), as determined by ELISA. (F) Proportion of MerTK+HLA-DR± monocytes that efferocytosed apoptotic neutrophils, phagocytosed E. coli bioparticles and produced tumour necrosis factor (TNF)-α after microbial challenge (n=5 each). Non-parametric (Mann-Whitney) statistical analysis was used. Data presented as median values with IQR. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. SSC, side scatter; FSC, forward scatter.
proinflammatory (eg, tumour necrosis factor (TNF)-α) mediators following microbial challenge (figure 1E, F, and see online supplementary figure S1B).

**Gene expression profile of MerTK+ monocytes in ALF**

To fully characterise the MerTK+ population in ALF, we performed FACS-sorting of MerTK+ monocytes from HC and ALF (figure 2A) and subjected these cells to a quantitative gene expression array. Compared with MerTK−, MerTK+ monocytes at steady state (figure 2B, C), and in ALF (see online supplementary figure S2), have a transcriptional profile consistent with a more differentiated ‘tissue-like’ phenotype, characterised by a significant upregulation of genes responsible for adhesion (eg, ICAM2, ITGA4, ITGB1), phagocytosis/pattern-recognition (FCGR2A/C, FCGR3A/B) and cytokines/chemokines (CCL5, PTGS2, TNF) (figure 2D, E). Moreover, these cells maintain an M2-like skewed profile (eg, CD163, MARCO, MRC1), activation of the downstream MerTK/cytokine signalling pathway (IRF3, JAK3) with a concomitant downregulation in genes linked with cell activation (NLRP3, SMAD3, SRC) (figure 2D, E).

**MerTK+ macrophages are important in the resolution of acute liver injury**

We employed multispectral and confocal imaging to delineate the topography and phenotype of MerTK+ macrophages in human ALF liver tissue. Compared with pathological controls, we confirm a numerical increase of MerTK+ cells, of monocyte/macrophage lineage (CD163+), that localise to areas of centrilobular necrosis in the ALF liver (figure 3A and see online supplementary figure S3A). In non-acutely inflamed tissue, the proportion of MerTK+ cells derived from infiltrating monocytes (MAC387+MerTK+) was <39%. Interestingly, the proportion of these circulatory derived cells was cells was in ALF explant tissue (figure 3A and see online supplementary figure S3C). Similar to other models of sterile liver injury, we show that these avidly phagocytic (figure 1F) MerTK+ macrophages infiltrate and form ring-like structures around necrotic areas in the ALF liver (figure 3A).

Given our data demonstrating a marked expansion of MerTK+ cells in human ALF, with resolution-like properties, we sought to determine their biological relevance in acute liver injury, using APAP-treated WT and Mer-deficient (Mer−/−) mice. First, by applying UPLC-MS on plasma derived from both groups (baseline vs 8 hours post APAP), we show that WT and Mer−/− mice have no differences in APAP metabolite concentrations, indicating that the Mer−/− do not differ in their APAP metabolism (see online supplementary figure S4). Next, we examined the temporal expression and immunophenotype of MerTK+ hepatic macrophages in WT mice (figure 3B, E). Here, we identify an increase in the overall proportion of F4/80+CD11b+Ly6G−MerTK+ macrophages at 24 and 48 hours after APAP administration (figure 3B). Using established gating strategies, we demonstrate that the increase in MerTK+ cells is predominantly on the resident KC population (figure 3D). Compared with M0MF, MerTK+ KC are characterised by a MHClow expression profile (figure 3D) which is associated with highly phagocytic and prorrestorative capabilities and bears striking similarities to the MerTK+ phenotype observed in patients with ALF (figure 1D). Thus, KC greatly contribute to the increased proportion of MerTK+MHClow macrophages detected at 24 and 48 hours following APAP treatment (figure 3E).

However, APAP administration in Mer−/− mice resulted in a significantly higher and persistent degree of acute liver injury, compared with WT mice (figure 4A). Mer−/− mice had a significantly lower proportion of F4/80+ hepatic macrophages at steady state and following APAP dosing (figure 4B) that was attributable to a depletion in the proportion of MHClow/Ly6Glow expressing resident KCs (figure 4B, C and see online supplementary figure S1D). In keeping with its role for neutrophil homeostasis and clearance, mice lacking MerTK displayed a significantly higher number of activated (MPO+) and proportion of Ly6G+ neutrophils at peak (8 hours) and resolution phases (24 hours) of APAP-induced liver injury, when compared with WT mice (figure 4D, E).
MerTK+ macrophages can be induced by the microenvironmental mediator SLPI in vitro

Given the marked upregulation of MerTK within the ALF liver, we sought to examine whether the key microenvironmental mediator SLPI, released by monocytes/macrophages in ALF (figure 1E), could be responsible for its induction. We show that SLPI induces MerTK+HLA-DR-high monocytes following their transmigration across activated hepatic endothelium (figure 5A, B), a phenotype that is also recapitulated in human liver-derived hepatic macrophages (figure 5C). Important,
Figure 3  Mer tyrosine kinase (MerTK)+ hepatic macrophages are expanded in human and experimental APAP-induced acute liver injury. (A) Representative confocal images for MerTK (green), CD163 (red), HLA-DR (red), DAPI (blue) and colocalisation (yellow) in pathological control (n=4) and acute liver failure (ALF) (n=6) human liver tissue (100×, inset 200×). Data show enumeration of CD163+MerTK+ and MerTK+HLA-DR+ cells in centrilobular areas of pathological control (PC, n=4) and ALF (n=6) liver. (B–E) Wild-type (WT) mice dosed with APAP were studied at 8, 24 and 48 hours, while untreated mice served as baseline controls (n=4/group). (B) Schematic of experimental dosing, representative flow cytometry analysis and gating strategy used to identify F4/80+ hepatic macrophages and determine their MerTK expression levels. (C) Ly6G+ neutrophils and F4/80+ macrophages as percentage (%) of total liver CD45+ leucocytes, as determined by flow cytometry. (D) Representative flow cytometry gating strategy used to identify (CD11b\text{low}F4/80\text{high})-resident Kupffer cells (KC) and (CD11b\text{high}F4/80\text{low}) monocyte-derived macrophages (MoMF) to determine their MerTK expression. Further subanalysis examined the MHC class II and Ly6C expression levels of MerTK+ macrophages in both MoMF (grey bars) and KC (black bars) subpopulations. (E) Data show MerTK+MHCII+ macrophages as proportion of total F4/80+ cells and the relative contribution of MoMF (grey) or KC (black). Non-parametric (Mann-Whitney) statistical analysis was used. Data are presented as median values with IQR. * or \#p<0.05, **p<0.01, ****p<0.0001.
these cells exhibit augmented secretion of anti-inflammatory/proresolving (interleukin (IL)-10, transforming growth factor (TGF)-β1, hepatocyte growth factor (HGF)) mediators but attenuated levels of proinflammatory factors (interferon (IFN)-γ, TNF-α, IL-6) (figure 5D).

SLPI-induced MerTK+ macrophages suppress neutrophil activation and promote their clearance

Having detected a higher number of apoptotic neutrophils in the ALF liver (figure 6A), we performed a series of experiments to determine whether SLPI can also modulate neutrophil...
activation and their subsequent clearance. We confirm that SLPI does not directly alter neutrophil survival, TLR-evoked inflammatory responses and reactive oxygen species production (see online supplementary figure 5A,B). However, in line with recent reports,32 SLPI directly (at physiological concentrations detected in ALF) reduced the formation of neutrophil extracellular traps (NETosis) following stimulation with either phorbol myristate acetate (PMA) or LPS (figure 6B). To evaluate whether MerTKhigh cells modulate neutrophil function in a paracrine manner (figure 6C), we assessed the effects of soluble mediators released from healthy SLPI-treated and ALF monocytes on neutrophils (figure 6B, D). Neutrophils cultured in supernatants derived from SLPI-treated and ALF monocytes had a significantly reduced survival, LPS-stimulated secretion (TNF-α) and increased PMA-evoked NETosis (figure 6E).

In addition to suppressing neutrophil activation, SLPI also augments their clearance. Similar to MerTK+HLA-DRhigh cells in patients with ALF (figure 1F), both SLPI-treated and dexamethasone-treated (positive control)33 monocytes exhibited enhanced uptake of apoptotic neutrophils (efferocytosis) (figure 7A, D), but not hepatocytes, when compared with untreated cells (figure 7E-F). Together, we identify that SLPI fulfills the criteria as a proresolving mediator34 in ALF through the induction of a MerTK+HLA-DRhigh phenotype which (a) counter-regulates the production of proinflammatory cytokines while promoting resolution/tissue-repair mediator release, (b) suppresses neutrophil activation and NET formation, (c) induces neutrophil apoptosis and enhances their subsequent clearance.

SLPI induces MerTK+ macrophages in vivo and promotes resolution following acute liver injury

We determined whether prorestorative MerTK+ macrophages could be induced by exogenous SLPI administration in mice using the experimental model of ALF. We found comparable biochemical and histological indices of liver injury at 24 hours

Figure 5  Secretory leucocyte protease inhibitor (SLPI) induces a Mer tyrosine kinase (MerTK)highHLA-DRhigh phenotype in monocytes and liver-derived macrophages. (A–B) Effects of recombinant human (rh)-SLPI (0 and 0.5 μg/mL) on monocyte migration across hepatic endothelium were determined (n=3 independent experiments). (A) Schematic of migration assay; CD14-isolated monocytes are added on top of a preformed hepatic endothelium monolayer; non-migrated monocytes are harvested 1.5 hours after, while subendothelial monocytes are obtained 24 hours later. Phenotypic characterisation of non-migrated and subendothelial monocytes was determined by flow cytometry. (B) Data show HLA-DR, CD163 and MerTK expression levels and representative histograms (CD14++CD16+ subset) for (top panel) non-migrated and (lower panel) subendothelial monocytes. Results expressed as mean fluorescence intensity (MFI). (C and D) Effects of (rh)-SLPI (0 and 0.5 μg/mL) on hepatic macrophages isolated from normal liver explant tissue were assessed (n=5). (C) Data show representative histograms and surface marker expression in the CD14+CD16+ subset and intracellular cytokine levels in total monocytes following microbial challenge (LPS 100 ng/mL). (D) LPS-stimulated inflammatory cytokine levels (pg/mL) in hepatic mononuclear cell culture supernatants, as determined by ELISA. Non-parametric (Mann-Whitney) statistical analysis was used. Data presented as median values with IQR. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. IFN, interferon; IL, interleukin; iso, isotype control antibody; ns, non-significant; TNF, tumour necrosis factor; .

Triantafyllou E, et al. Gut 2018;67:333–347. doi:10.1136/gutjnl-2016-313615

Hepatology

on September 22, 2023 by guest. Protected by copyright.http://gut.bmj.com/ Gut: first published as 10.1136/gutjnl-2016-313615 on 27 April 2017. Downloaded from http://gut.bmj.com/ on September 22, 2023 by guest. Protected by copyright.
Figure 6  Secretory leucocyte protease inhibitor (SLPI) suppresses neutrophils through Mer tyrosine kinase (MerTK)^{high}HLA-DR^{high} monocytes in a paracrine manner. (A) Representative immunohistochemistry (IHC) (left) and confocal (right) micrographs and enumeration of (MPO+) hepatic neutrophils and (MPO+TUNEL+) apoptotic neutrophils in centrilobular areas of pathological control (PC, n=4) and acute liver failure (ALF) (n=6) human liver tissue. IHC images (400×) show MPO+ (purple) cells. Confocal images show MPO (green), TUNEL (red), DAPI (blue) and coexpression (yellow) (400×). (B–E) Autocrine and paracrine effects of recombinant human (rh)-SLPI (0 and 0.5 μg/mL) on neutrophils were examined (n=5). (B) Neutrophil extracellular trap formation (NETosis) was determined fluorometrically (DNA, ng/mL) in culture following stimulation with PMA (25nM) or LPS (100 ng/mL). (Left) Representative images of NETs using SYTOX Green Dye (1 μM). (Right) Data show NETosis (DNA, ng/mL) quantified in culture (1) with/without SLPI and (2) with ±SLPI-treated monocyte culture supernatants (n=3). (C) Paracrine experimental approach for neutrophils and data showing monocyte MerTK expression levels after culture with/without SLPI (48 hours). (D) Representative Annexin-V/7-AAD staining and percentage of apoptotic neutrophils in culture with ±SLPI-treated monocyte supernatants (n=5). (E) SLPI paracrine effects were assessed by blocking SLPI’s activity on monocytes in ALF plasma (α-SLPI, 5 μg/mL) (n=5). (Left) Representative Annexin-V/7-AAD staining and percentage of apoptotic neutrophils; (middle) NET formation (DNA, ng/mL) and (right) LPS-stimulated (100 ng/mL) intracellular cytokine levels of neutrophils (n=5 each). Data presented as median values with IQR. *p<0.05, **p<0.01, ****p<0.0001. HC, healthy controls; IL, interleukin; ns, non-significant; TNF, tumour necrosis factor.
between APAP and APAP+SLPI-treated mice (figure 8A, B). However, SLPI administration in APAP mice led to a significant reduction in those indices during the resolution phase (48-hour timepoint) of APAP-induced injury (figure 8A, B). To examine whether SLPI induces resolution-like macrophages in vivo, as described in vitro (figure 5A–C), we determined the MerTK expression levels of (F4/80+) hepatic macrophages at steady state and during APAP-induced acute liver injury with/without SLPI administration (figure 8C, D). Here, we show that SLPI induces an increase in the (F4/80+) overall proportion of MerTK+ macrophages at steady state (figure 8C) and at 48 hours post APAP dose (figure 8D). Furthermore, the increase in MerTK expressing macrophages following SLPI treatment is confined to the resident KC population (figure 8D).

In view of the data identifying the mechanisms by which SLPI promotes neutrophil death and clearance, we also examined the
number of apoptotic neutrophils in APAP mice using immuno-
histochemistry and confocal imaging. SLPI-treated APAP mice
had a significantly lower number of MPO+ cells and higher pro-
portion of apoptotic neutrophils (MPO+TUNEL+) at 24 and
48 hours, when compared with APAP mice (figure 8E, F). Taken
together, our results reveal that during APAP-induced liver injury
in mice, SLPI administration promotes resolution responses by
imprinting a resolution-like, MerTK+, hepatic macrophage
phenotype and modulates neutrophil activation and survival.

**DISCUSSION**

We describe an expansion of monocytes and hepatic macro-
phages that exhibit an immune-regulatory MerTK+HLA-DRhigh
phenotype with resolution-like characteristics, detected in both
circulatory and tissue compartments of patients with ALF. We
also show that these cells infiltrate the inflamed liver and form
ring-like structures around areas of hepatic necrosis. In line with
other models of acute tissue injury, functional analyses of these cells reveal that they possess suppressed innate immune

---

**Figure 8** Secretory Leucocyte protease inhibitor (SLPI) administration in wild-type (WT) mice induces Mer tyrosine kinase (MerTK)+ macrophages and promotes hepatic resolution following APAP-induced acute liver injury. WT mice were dosed with SLPI (+/+), APAP (+/−) or APAP plus SLPI (+/+), while untreated mice (−/−) served as baseline controls (n=6/group). Mice were studied at baseline (white bars), 24 hours (black bars) and 48 hours (grey bars). (A) Schematic describes the experimental dosing and representative images of H&E-stained livers (baseline and 48 hours). (B) Quantification of necrosis and plasma alanine transaminase (ALT) levels. (C) Representative flow cytometry analysis and data show MerTK expression of F4/80+ macrophages at baseline and following SLPI administration. (D) Data show MerTK expression levels of F4/80+ macrophages, subanalysed into (CD11bhighF4/80high)-resident Kupffer cells (KC) and (CD11blowF4/80low) monocyte-derived macrophages (MoMF). (E) Representative liver immunohistochemistry images at baseline and 24 hours (n=5 each) and enumeration of MPO+ (purple) hepatic neutrophils (200×). (F) Representative liver confocal micrographs at baseline and 24 hours (n=5 each) stained for MPO (green), TUNEL (red), DAPI (blue); coexpression (yellow) (400×). Data show the percentage of (MPO+TUNEL+) apoptotic neutrophils. Non-parametric (Mann-Whitney) statistical analysis was used. Data are presented as median values with IQR. * or #p<0.05, **p<0.01, **** p<0.0001. SSC, side scatter.

Triantafyllou E, et al. Gut 2018;67:333–347. doi:10.1136/gutjnl-2016-313615
but enhanced resolution responses, typified by augmented clear-
ance of cellular/infective material and secretion of anti-
flammatory/tissue-repair mediators (eg, SLPI) but reduced proinflammatory cytokines (eg, TNF-α). In line with previous
data,24 comparison of gene expression profiles between MerTK+
and MerTK− monocytes in steady state and ALF reveal that
they possess a more differentiated lineage ‘tissue-like’ profile,
with increased expression of a number of genes associated with
innate and adaptive effector functions.

Our data demonstrate marked elevations in circulating levels of
MerTK+ cells in patients with both acetaminophen-induced
and non-acetaminophen induced ALF, with highest MerTK
levels detected in patients with AALF with a greater severity of
acute liver injury and adverse clinical outcome. Peak circulating
MerTK levels are detected early on admission to our unit,
which may reflect the extent of hepatic tissue resolution
responses following acute hepatocellular necrosis. Future pro-
spective studies are warranted to assess the utility of circulating
MerTK levels as an early mechanistic biomarker of resolution
responses and outcome in patients with acute liver injury.

Our data from the experimental model for this disease are
first to provide novel insights into the origin and biological rele-
ance of these regulatory cells during acute hepatic injury. Here,
we show that the proportion of MerTK-expressing cells are spe-
cifically increased in the resident KC, and not infiltrating macro-
phage, population following APAP-induced acute liver injury.
Moreover, MerTK+ KCs bear a MHCClass IIhighLy6Clow
phenotype which is the dominant phagocytic14 28 and prores-
storative25 29 hepatic macrophage population and bears striking similarities with the ‘prophagocytic’ MerTK+HLA-DRhigh
cells in human ALF. Furthermore, while the proportion of monocyte-
derived macrophages expressing MerTK does not substantially
increase in acute liver injury, these cells also acquire the
MHCClassIIhighLy6Clow phenotype, in line with their role in
resolving inflammation.6 7

We demonstrate that Mer-deficient mice have a reduced pro-
portion of resident KCs prior to and following APAP adminis-
tration. In view of its role in promoting cell survival through
activation of antiapoptotic pathways,38 these data suggest that
activation of MerTK in KCs is of importance in differentiation
and restoration following acute liver injury. Further studies are
warranted to identify the precise mechanisms through which
MerTK regulates this process in both human and experimental
models of disease.

Our findings in APAP-treated Mer-deficient mice echo recent
data showing that MerTK promotes resolution responses by
dampening innate responses and augmenting clearance of neu-
rophils following acute tissue injury.10 19 40 In the absence of
MerTK, we report a significant depletion in hepatoprotective
resident macrophages12 13 (MHCClass IIhighLy6Clow) with the
highest phagocytic capabilities,28 a reciprocal increase in hepatic
neutrophils and persistent necrosis following APAP administra-
tion. Taken together, these data indicate that MerTK-
bearing cells identify a hepatic macrophage population with
enhanced phagocytic capabilities that evolve following acute
hepatocellular necrosis serving to drive hepatic resolution
responses.

In both experimental and human models of ALF, we identify
SLPI as a microenvironmental mediator that critically regulates
the interplay between myeloid cells to promote hepatic reso-
lution responses through the induction of a MerTKhigh
phenotype. Specifically, we show that SLPI selectively induces MerTK
expression in the resident KCs while concomitantly increasing the
number of apoptotic neutrophils. However, there are no
data on how SLPI modulates neutrophil function. Here, we
demonstrate that SLPI induces neutrophil apoptosis in a para-
crine manner and augments their subsequent clearance through
MerTKhigh cells. The effect of SLPI on cell clearance appears to
be highly selective in view of the fact that it does not alter clear-
ance of APAP-treated apoptotic or necrotic parenchymal cells.
Furthermore, we determined that SLPI can also drive resol-
sion responses through attenuation of NET formation, a process
that has been shown to exacerbate acute tissue damage through
activation of the inflammasome in ischaemia–reperfusion
injury.31 Further studies are required to examine the role of
NEToxis in modulating myeloid cell activation and its effects on
acute liver injury.

Although anti-inflammatory programmes initiated following
apoptotic cell uptake are beneficial in resolving tissue injury,
they have the undesirable potential to dampen antimicrobial
responses.25 Our data support this notion as we demonstrate
that acute liver injury reprogrammes myeloid cells towards
MerTK-dependent resolution responses, which quell tissue
inflammation and promote the clearance of debris, while at
the same time suppress antimicrobial responses. Indeed, com-
parisons of MerTK transcriptional and functional profiles
between ALF and healthy controls reveal striking differences.
Here, MerTK+ monocytes in ALF have significant reductions
in immune pathways associated with innate immune recogni-
tion, signalling, antigen presentation with a concomitant upreg-
ulation of M2-like and downstream MerTK signalling
pathways. Taken together, we propose that circulating mono-
cytes are specifically reprogrammed during ALF following activ-
ation of MerTK-dependent resolution responses.24 25 42
Further research is required to delineate the precise mechan-
isms of monocyte reprogramming in response to overwhelming
infection.

The functional ‘reorientation’ of myeloid cells is likely to be
of pathogenic relevance in ALF, a condition that is charac-
terised by systemic immune dysregulation, immuneparesis and
a marked susceptibility to secondary infections.4 11 Here, we
also detect expanded numbers of MerTK+HLA-DR− cells, an
immune cell subset with impaired innate responses to micro-
bial challenge, during the evolution of human ALF. Given
their enhanced lymph node and tissue homing receptor expres-
sion, it is tempting to speculate that these cells are generated
following reprogramming within the inflamed liver and subse-
quent home to extrahepatic and circulatory compartments
where they serve to suppress antimicrobial responses.43 Further
work is required to delineate the recruitment and subsequent
fate of MerTK-expressing myeloid cells during acute liver
injury.

This work identified the induction of a proresorptive
MerTK-positive cell subset in ALF that may promote

tissue-repair responses, with implications for therapeutic inter-
vention, where enhancing the local function of these cells could
promote liver repair/regeneration. In this study, we used the pro-
resolving actions of SLPI as proof-of-principle in order to high-
light the biological significance of the MerTK+ phenotype in
promoting resolution responses following acute liver injury.
Using targeted strategies to harness the proresorptive capa-
bilities of MerTK+ cells represents a promising therapeutic avenue
in promoting tissue repair potentially in a number of acute
hepatic inflammatory disorders. However, caution would need
to be exercised when considering any of these therapeutic
approaches, given the evidence of peripheral monocyte suppres-
sion in ALF,11 42 indicating that the timing of therapy would
need to be carefully calibrated in order to promote resolution
while minimising the impact on immuneparesis. The balance of these biological processes must be rationalised when considering interventional strategies that promote liver repair processes while not exacerbating the risk of infection.

In conclusion, our data describe a marked expansion of a pro-inflammatory MerTK+ phenotype in circulating monocytes and tissue-resident macrophages in ALF. These immunoregulatory cells evolve in response to acute liver injury and represent a novel immunotherapeutic target in acute hepatic injury to quell tissue-destructive responses and promote resolution. Furthermore, we show that SLPI acts as a key mediator in regulating the function of hepatic myeloid cells, to promote resolution responses through induction of MerTK expression within the resident macrophage population.

Author affiliations
1Institute of Liver Studies, King’s College Hospital, King’s College London, London, UK
2Division of Digestive Diseases, St Mary’s Hospital, Imperial College London, London, UK
3National Institute for Health Research Birmingham Liver Biomedical Research Unit, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
4Division of Immunology and Inflammation, Department of Surgery and Cancer, Imperial College London, London, UK
5Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK

Acknowledgements
The authors gratefully acknowledge Dr Richard Parker and Isobelle Grant for technical and methodological support, and all patients that participated in the study. They thank the University College London (UCL) Nanosting Facility for providing the nCounter system and related services, and St Mary’s NHLI FACS core facility and Dr Yanping Guo for support and instrumentation. They also thank the Medical Research Council and the Rosettes Charitable Trust for ongoing funding support. They are grateful to King’s College Hospital Research and Development, the Imperial National Institute of Health Research Biomedical Research Centre and the NIHR Birmingham Biomedical Research Unit for infrastructure support. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.

Contributors
Study concept and design: ET, JW, MRT, DHA, CJW and CGA. Obtained funding: CGA. Study concept and design: ET, JW, MRT, DHA, CJW and CGA. Contributed to the acquisition of data: ET, JW, MRT, DHA, CW and CGA. Acquisition, analysis and interpretation of data: ET, OTP, LAP, AW, GP, CB, WK, RD, SMC, JW, MRT, DHA, CW and CGA. Manuscript draft: ET and CGA. Critical revision of manuscript: ET, JW, MRT, DHA, CW and CGA. Obtained funding: CGA.

Funding
Supported by the Medical Research Council (MR/K010514/1) and the Rosettes Charitable Trust (JS151/M439F-1).

Competing interests
None declared.

Ethics approval
NRES Health Research Authority (12/LO/0167).

Provenance and peer review
Not commissioned; externally peer reviewed.

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

1. Bernal W, Lee WM, Wendon J, et al. Acute liver failure: a curable disease by 2024? J Hepatol 2015;62(1 Suppl):S112-20.
2. Antoniades CG, Berry PA, Wendon JA, et al. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008;49:845-61.
3. Vaquero I, Polson J, Chour C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003;125:755-64.
4. Antoniades CG, Quaglia A, Taams LS, et al. Source and characterization of hepatic macropages in acetaminophen-induced acute liver failure in humans. Hepatology 2012;56:735-46.
5. Eipelmann S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014;41:21-35.
6. Zigmor E, Samia-Ginberg S, Pasmanik-Chor M, et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. J Immunol 2014;193:344-53.
7. Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008;84:1410-21.
8. Choi DY, Ban JD, Kim SC, et al. CCR5 knockout mice with C57BL6 background are resistant to acetaminophen-mediated hepatotoxicity due to decreased macropage migration into the liver. Arch Toxicol 2015;89:211-20.
9. Dambach DM, Watson LM, Gray KR, et al. Role of CR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology 2002;35:1093-103.
10. Mossanen JC, Krentel O, Ergen C, et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology 2016;64:1667-73.
11. Antoniades CG, Khamiri W, Abeles RD, et al. Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology 2014;59:1564–76.
12. Ju C, Reilly TP, Bouri M, et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol 2002;15:1504–13.
13. You Q, Holt M, Yin H, et al. Role of hepatic resident and infiltrating macrophages in liver repair after acute injury. Biochem Pharmacol 2013;86:836-43.
14. David BA, Rezende RM, Antunes MM, et al. Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice. Gastroenterology 2016;151:1176–91.
15. Rothlin CV, Carrera-Silva EA. Inflammation and cancer: the role of receptor signaling in immune homeostasis. Annu Rev Immunol 2015;33:355–91.
16. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327–36.
17. Zagórska A, Travers PG, Lew ED, et al. Diversification of TAM receptor tyrosine kinase function. Nat Immunol 2014;15:920–8.
18. Scott A, Weldon S, Taggart CC, SLPI and elafin: multifunctional antiproteases of the WDFC family. Biochem Soc Trans 2011;39:1437–40.
19. Ashcroft GS, Lei KJ, Jin WW, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000;6:1147–53.
20. Sallenave JM. Secretory Leukocyte Protease Inhibitor and Elafin/Trappin-2 Versatile Mucosal Antimicrobials and Regulators of Immunity. Am J Respi Cell Mol Biol 2010;42:635–43.
21. Nakamura A, Mori Y, Hagiwara K, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003;197:669–74.
22. Majchrzak-Gorecka M, Majewski P, Gryger B, et al. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. Cytokine Growth Factor Rev 2016;28:79–93.
23. Bernal W, Donaldson N, Wynoll D, et al. Blood lactate as an early predictor of outcome in paraacetamol-induced acute liver failure: a cohort study. Lancet 2002;359:558–63.
24. Bermeiecr C, Pop OT, Singanayagam A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERK. Gastroenterology 2014;138:103–15 e14.
25. Dal-Secco D, Wang J, Zeng Z, et al. A dynamic spectrum of monocytes arising from the in situ reprogramming ofCCR2+ monocytes at a site of sterile injury. J Exp Med 2015;212:447–56.
26. Mori Y, Izawa T, Takenaka S, et al. Participation of functionally different macrophage populations and monocyte chemoattractant protein-1 in early stages of thisaotamine-induced rat hepatic injury. Toxicol Pathol 2009;37:463–73.
27. Ramachandran P, Pellicoro A, Verno MA, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA 2012;109:E3186–95.
28. Stutchfield BM, Antoone DJ, Mackinnon AC, et al. CF1 restores innate immunity after liver injury in mice and serum levels and outcomes of patients with acute liver failure. Gastroenterology 2015;149:1896–909 e14.
29. Dragomir AC, Sun R, Choi H, et al. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J Immunol 2012;189:9334–41.
30. Hong C, Kidaro Y, A-Gonzalez N, et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J Clin Invest 2012;122:337–47.
31. Zimmermann HW, Brens T, Weston CJ, et al. Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver. Hepatology 2016;63:233–46.
32. Zabieglo K, Majewksi P, Majchrzak-Gorecka M, et al. The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps. J Leukoc Biol 2015.
33. Zizzo G, Cohen PL. IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids. J Immunol 2013;190:5237–46.
Sugimoto MA, Sousa LP, Pinho V, et al. Resolution of inflammation: what controls its onset. *Front Immunol* 2016;7:160.

Wan E, Yeap XY, Dehn S, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. *Circ Res* 2013;113:1004–12.

Lee YJ, Lee SH, Youn YS, et al. Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. *Toxicol Appl Pharmacol* 2012;263:61–72.

Choi JY, Park HJ, Lee YJ, et al. Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. *J Pharmacol Exp Ther* 2013;344:447–58.

Anwar A, Keating AK, Joung D, et al. Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. *J Leukoc Biol* 2009;86:73–9.

Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. *Nat Immunol* 2015;16:907–17.

Choi JY, Seo JY, Yoon YS, et al. Mer signaling increases the abundance of the transcription factor LXR to promote the resolution of acute sterile inflammation. *Sci Signal* 2015;8:ra21.

Huang H, Tohme S, Al-Khafaji AB, et al. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. *Hepatology* 2015;62:600–14.

Antoniades CG, Berry PA, Davies ET, et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. *Hepatology* 2006;44:34–43.

Kastenmüller W, Torabi-Parizi P, Subramanian N, et al. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. *Cell* 2012;150:1235–48.